Biotie Therapies - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Biotie Therapies. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Biotie Therapies. The Group's principal activity is the research and development of drugs for dependence disorders, inflammatory diseases, glycomics applications and thrombosis. This is the Group's only segment. The Group's products focus on widespread diseases such as alcohol dependency, rheumatoid arthritis, inflammatory bowel disease, psoriasis, thrombosis and cancer. The Group's 'nalmefene' is the first tablet form drug demonstrating efficacy in reducing heavy drinking in multicenter. Other products include VAP-1 monoclonal which I s an antibody for inflammatory diseases, VAP-1 SSAO is enzyme inhibitor for inflammatory diseases and Integrin 2 B1 is inhibitor for thrombosis. The Group operates in Finland and Germany. The Group acquired CNS and inflammation specialist elbion GmbH in 2008.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report